PlumX Metrics
Embed PlumX Metrics

RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report

Frontiers in Oncology, ISSN: 2234-943X, Vol: 14, Page: 1360492
2024
  • 3
    Citations
  • 0
    Usage
  • 1
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    3
  • Captures
    1
  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

Division of Endocrinology Researchers Describe New Findings in Neuroendocrine Cancer (RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report)

2024 FEB 23 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Data detailed on neuroendocrine cancer have been presented. According

Article Description

Metastatic lung neuroendocrine carcinomas provide diagnostic challenges in identifying the cell of origin. High level calcitonin expression is not pathognomonic for medullary thyroid cancer. Tumor mutation analysis may provide essential clues regarding tissue origin and treatment targets. Oncogenic RET gene fusions have been identified in non-small cell lung cancer and non-medullary thyroid cancers, whereas RET point mutations are the key genetic finding in both inherited and sporadic MTC. Patients who receive radiation for the treatment of other cancers have an increased risk of developing a second malignancy, including a neuroendocrine carcinoma. Herein, we present a case of calcitonin-rich neuroendocrine carcinoma emerging on a background of prior radiation and chemotherapy for the treatment of Hodgkin’s disease. Identification of a RET gene rearrangement (KIF5B-RET) led to initial successful treatment with selpercatinib, with eventual resistance associated with an activating mutation involving the MEK1 protein (MAP2K1 p. E102-I103 del) that led to relapse and progression of the disease.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know